The New York Times reports on the landmark case against the Rochester Drug Cooperative and its CEO, the first instance of a pharmaceutical distributor facing federal criminal charges related to the opioid epidemic. The article provides an overview of the charges, which include conspiracy to distribute controlled substances and defrauding the DEA. It examines the broader implications of this case for the pharmaceutical industry and regulatory agencies. The piece highlights the efforts of law enforcement to hold companies accountable for their role in the opioid crisis, marking a significant step in addressing the epidemic.
Read the full article
